Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,581 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $52.98, for a total transaction of $613,561.38. Following the completion of the transaction, the chief financial officer now owns 39,153 shares of the company's stock, valued at approximately $2,074,325.94. This represents a 22.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, May 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.22, for a total transaction of $697,407.82.
• On Tuesday, April 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.50, for a total transaction of $330,058.50.
• On Wednesday, April 2nd, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.26, for a total transaction of $338,860.06.

Hims & Hers Health Trading Up 8.3%

NYSE HIMS traded up $4.34 during trading on Friday, hitting $56.74. 40,946,855 shares of the company's stock were exchanged, compared to its average volume of 19,737,954. The stock's 50 day moving average price is $39.85 and its two-hundred day moving average price is $36.01. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The company has a market cap of $12.70 billion, a PE ratio of 128.96 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same period in the prior year, the business earned $0.05 EPS. The company's revenue for the quarter was up 110.7% compared to the same quarter last year. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research analyst reports. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Needham & Company LLC reissued a "buy" rating and issued a $61.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Morgan Stanley reduced their target price on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 29th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health has an average rating of "Hold" and an average target price of $37.67.

Institutional Trading of Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in the stock. Crewe Advisors LLC bought a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Blume Capital Management Inc. grew its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health during the 1st quarter valued at $30,000. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.